GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 15991 participants.

Also called NCT01813435

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 15,991 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01813435
Other papers using this trial's data
  • Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial JAMA cardiology, 2020-01-01 DOI, PubMed 31693078, PMC7029729 Not in the PMC Open Access subset.
  • Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial JAMA cardiology, 2019-11-01 DOI, PubMed 31557763, PMC6764000 Not in the PMC Open Access subset.
  • Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial Journal of the American Heart Association, 2021-09-21 DOI, PubMed 34533034, PMC8649516 In the PMC Open Access subset under CC BY-NC-ND.
  • Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI Journal of the American College of Cardiology, 2019-10-22 DOI, PubMed 31623758
  • Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention Circulation. Cardiovascular interventions, 2020-09 DOI, PubMed 32838554
  • Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial European heart journal. Cardiovascular pharmacotherapy, 2020-07-01 DOI, PubMed 31876907
  • Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial Clinical research in cardiology : official journal of the German Cardiac Society, 2020-07 DOI, PubMed 31925529
  • Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy? Open heart, 2025-01-28 DOI, PubMed 39875171, PMC11781092 In the PMC Open Access subset under CC BY-NC.
  • Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2019-12-20 DOI, PubMed 30888959
  • Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS) The American journal of cardiology, 2021-01-01 DOI, PubMed 33065080
  • The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial Clinical research in cardiology : official journal of the German Cardiac Society, 2020-09 DOI, PubMed 32006156, PMC7449952 In the PMC Open Access subset under CC BY.
  • Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2020-04-03 DOI, PubMed 31845894

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Singapore, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01813435. Randomized; no masking; primary purpose treatment. Start 2013-07-01 (actual); primary completion 2015-11-09 (actual). Results posted on 2019-07-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Acetylsalicylic Acid
Intervention (Drug)
Clopidogrel
Lead sponsor
ECRI bv (class: industry)
Collaborator
Biosensors International (class: other)
Collaborator
AstraZeneca (class: industry)
Collaborator
The Medicines Company (class: industry)

Record details

Record id
cardio:ct-nct01813435
Content hash
d0f4203502331f19178ef30ffd67e115ad4fea94d822a12d87afbfa69b5bd36c